CA2436692A1 - Oral extended release formulation of gepirone - Google Patents
Oral extended release formulation of gepirone Download PDFInfo
- Publication number
- CA2436692A1 CA2436692A1 CA002436692A CA2436692A CA2436692A1 CA 2436692 A1 CA2436692 A1 CA 2436692A1 CA 002436692 A CA002436692 A CA 002436692A CA 2436692 A CA2436692 A CA 2436692A CA 2436692 A1 CA2436692 A1 CA 2436692A1
- Authority
- CA
- Canada
- Prior art keywords
- gepirone
- amount
- extended release
- formulation
- tablets
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- QOIGKGMMAGJZNZ-UHFFFAOYSA-N gepirone Chemical compound O=C1CC(C)(C)CC(=O)N1CCCCN1CCN(C=2N=CC=CN=2)CC1 QOIGKGMMAGJZNZ-UHFFFAOYSA-N 0.000 title claims abstract 9
- 229960000647 gepirone Drugs 0.000 title claims abstract 9
- 238000013265 extended release Methods 0.000 title claims abstract 5
- 238000009472 formulation Methods 0.000 title claims abstract 5
- 239000000203 mixture Substances 0.000 title claims abstract 5
- 239000011159 matrix material Substances 0.000 claims abstract 5
- 229920000642 polymer Polymers 0.000 claims abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract 3
- 208000012902 Nervous system disease Diseases 0.000 claims abstract 2
- 239000011230 binding agent Substances 0.000 claims abstract 2
- 150000001720 carbohydrates Chemical class 0.000 claims abstract 2
- 208000015114 central nervous system disease Diseases 0.000 claims abstract 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00204388.3 | 2000-12-08 | ||
| EP00204388 | 2000-12-08 | ||
| PCT/EP2001/014189 WO2002045753A2 (en) | 2000-12-08 | 2001-11-30 | Oral extended release formulation of gepirone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2436692A1 true CA2436692A1 (en) | 2002-06-13 |
Family
ID=8172397
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002436692A Abandoned CA2436692A1 (en) | 2000-12-08 | 2001-11-30 | Oral extended release formulation of gepirone |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1343504A2 (cs) |
| JP (1) | JP2004517083A (cs) |
| KR (1) | KR20040018314A (cs) |
| CN (1) | CN1479620A (cs) |
| AR (1) | AR031461A1 (cs) |
| AU (1) | AU2002226371A1 (cs) |
| BR (1) | BR0115976A (cs) |
| CA (1) | CA2436692A1 (cs) |
| CZ (1) | CZ20031589A3 (cs) |
| EC (1) | ECSP034627A (cs) |
| HU (1) | HUP0401021A2 (cs) |
| IL (1) | IL155855A0 (cs) |
| MX (1) | MXPA03005099A (cs) |
| NO (1) | NO20032581L (cs) |
| PL (1) | PL362445A1 (cs) |
| RU (1) | RU2003120446A (cs) |
| SK (1) | SK6942003A3 (cs) |
| WO (1) | WO2002045753A2 (cs) |
| ZA (1) | ZA200303915B (cs) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004028507A1 (en) * | 2002-09-24 | 2004-04-08 | Akzo Nobel N.V. | Method to improve pharmaceutical tablets having a matrix of cellulose ether |
| AU2004324868B2 (en) * | 2004-11-05 | 2010-04-29 | Fabre Kramer Holdings Inc | High-dosage extended-release formulation of gepirone |
| MY198454A (en) * | 2017-07-26 | 2023-08-29 | Abbott Lab | Nutritional Tablets and Methods of Making the Same |
| CN109745323A (zh) * | 2017-11-01 | 2019-05-14 | 四川科瑞德制药股份有限公司 | 氮哌酮类化合物提高副交感神经活性的用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5478572A (en) * | 1994-09-06 | 1995-12-26 | Bristol-Myers Squibb Co. | Gepirone dosage form |
-
2001
- 2001-11-30 CZ CZ20031589A patent/CZ20031589A3/cs unknown
- 2001-11-30 PL PL01362445A patent/PL362445A1/xx not_active Application Discontinuation
- 2001-11-30 BR BR0115976-3A patent/BR0115976A/pt not_active Application Discontinuation
- 2001-11-30 RU RU2003120446/15A patent/RU2003120446A/ru not_active Application Discontinuation
- 2001-11-30 CN CNA018201792A patent/CN1479620A/zh active Pending
- 2001-11-30 SK SK694-2003A patent/SK6942003A3/sk unknown
- 2001-11-30 AU AU2002226371A patent/AU2002226371A1/en not_active Abandoned
- 2001-11-30 KR KR10-2003-7007555A patent/KR20040018314A/ko not_active Withdrawn
- 2001-11-30 MX MXPA03005099A patent/MXPA03005099A/es unknown
- 2001-11-30 CA CA002436692A patent/CA2436692A1/en not_active Abandoned
- 2001-11-30 HU HU0401021A patent/HUP0401021A2/hu unknown
- 2001-11-30 EP EP01995688A patent/EP1343504A2/en not_active Withdrawn
- 2001-11-30 JP JP2002547535A patent/JP2004517083A/ja not_active Withdrawn
- 2001-11-30 IL IL15585501A patent/IL155855A0/xx unknown
- 2001-11-30 WO PCT/EP2001/014189 patent/WO2002045753A2/en not_active Application Discontinuation
- 2001-12-07 AR ARP010105683A patent/AR031461A1/es not_active Application Discontinuation
-
2003
- 2003-05-20 ZA ZA200303915A patent/ZA200303915B/en unknown
- 2003-05-28 EC EC2003004627A patent/ECSP034627A/es unknown
- 2003-06-06 NO NO20032581A patent/NO20032581L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0401021A2 (hu) | 2004-09-28 |
| NO20032581D0 (no) | 2003-06-06 |
| KR20040018314A (ko) | 2004-03-03 |
| MXPA03005099A (es) | 2004-02-12 |
| EP1343504A2 (en) | 2003-09-17 |
| AU2002226371A1 (en) | 2002-06-18 |
| NO20032581L (no) | 2003-06-06 |
| SK6942003A3 (en) | 2003-10-07 |
| ZA200303915B (en) | 2004-08-20 |
| BR0115976A (pt) | 2003-12-30 |
| IL155855A0 (en) | 2003-12-23 |
| WO2002045753A2 (en) | 2002-06-13 |
| JP2004517083A (ja) | 2004-06-10 |
| ECSP034627A (es) | 2004-09-28 |
| AR031461A1 (es) | 2003-09-24 |
| CZ20031589A3 (cs) | 2003-11-12 |
| PL362445A1 (en) | 2004-11-02 |
| WO2002045753A3 (en) | 2002-08-29 |
| CN1479620A (zh) | 2004-03-03 |
| RU2003120446A (ru) | 2005-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0914119B1 (en) | Process for forming solid oral dosage forms of valsartan | |
| US6103263A (en) | Delayed pulse release hydrogel matrix tablet | |
| JP2638389B2 (ja) | 経口投与後のインダパミドの徐放性マトリックス錠剤 | |
| EP0744942A1 (en) | Controlled release hydrogel formulation | |
| KR100465895B1 (ko) | 파라세타몰을 포함하는 경구용 정제 | |
| WO2004110422A1 (en) | Extended-release tablets of metformin | |
| AU5748299A (en) | Pharmaceutical composition comprising entacapone or nitecapone as well as a cross-linked cellulose derivative | |
| HUP0301390A2 (hu) | Valzartánt tartalmazó orális gyógyászati készítmény | |
| WO2006103551A1 (en) | Controlled release formulations of oxycodone | |
| JPH1036268A (ja) | 経口経路による投与後のチアネプチンナトリウム塩の持続性放出を可能とするマトリックス錠 | |
| CA2493593A1 (en) | Bicifadine formulation | |
| CA2436692A1 (en) | Oral extended release formulation of gepirone | |
| US20240415777A1 (en) | Instant release pharmaceutical preparation of anticoagulant and preparation method therefor | |
| US20030152621A1 (en) | Pharmaceutical formulation of gepirone for oral administration | |
| US4515802A (en) | Analgesic preparations | |
| HUT75461A (en) | Laxative compositions | |
| CA1229552A (en) | Cimetidine compositions | |
| WO2005092293A1 (en) | Formulations of metformin | |
| CN119868292A (zh) | 一种阿普斯特缓冲剂片剂组合物及其制备方法 | |
| WO2007047040A2 (en) | Directly compressible extended release alprazolam formulation | |
| HK1019858B (en) | Process for forming solid oral dosage forms of valsartan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |